141 related articles for article (PubMed ID: 35862378)
21. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.
Murai Y; Kawasuji H; Takegoshi Y; Kaneda M; Kimoto K; Ueno A; Miyajima Y; Kawago K; Fukui Y; Ogami C; Sakamaki I; Tsuji Y; Morinaga Y; Yamamoto Y
Int J Infect Dis; 2021 May; 106():33-35. PubMed ID: 33746092
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M;
Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615
[TBL] [Abstract][Full Text] [Related]
23. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
25. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
Papp H; Lanszki Z; Keserű GM; Jakab F
Geroscience; 2022 Jun; 44(3):1263-1268. PubMed ID: 35543795
[TBL] [Abstract][Full Text] [Related]
26. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
Tsuboi H; Kasamatsu Y; Matsubara S; Sasao A; Kunimitsu K; Munakata N; Ito T; Tsuchido Y; Yamawaki M; Fujita N
J Infect Chemother; 2021 Jul; 27(7):1072-1075. PubMed ID: 33814353
[TBL] [Abstract][Full Text] [Related]
27. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
[TBL] [Abstract][Full Text] [Related]
28. Strengthening the immunity of the Swiss population with micronutrients: A narrative review and call for action.
Berger MM; Herter-Aeberli I; Zimmermann MB; Spieldenner J; Eggersdorfer M
Clin Nutr ESPEN; 2021 Jun; 43():39-48. PubMed ID: 34024545
[TBL] [Abstract][Full Text] [Related]
29. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
[TBL] [Abstract][Full Text] [Related]
30. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
31. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
Stroehlein JK; Wallqvist J; Iannizzi C; Mikolajewska A; Metzendorf MI; Benstoem C; Meybohm P; Becker M; Skoetz N; Stegemann M; Piechotta V
Cochrane Database Syst Rev; 2021 May; 5(5):CD015043. PubMed ID: 34029377
[TBL] [Abstract][Full Text] [Related]
32. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
Turan DB; Menteş M; Özel Y; Şerefhanoğlu K; Aydoğan B; İbil N; Güneşdoğdu F; Orucova HM; Saltürk C; Çelik H
Braz J Infect Dis; 2022; 26(1):102328. PubMed ID: 35139366
[TBL] [Abstract][Full Text] [Related]
33. Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir.
El-Awady M; Elmansi H; Belal F; Shabana RA
J Fluoresc; 2022 Sep; 32(5):1941-1948. PubMed ID: 35771341
[TBL] [Abstract][Full Text] [Related]
34. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.
Fujii S; Ibe Y; Ishigo T; Inamura H; Kunimoto Y; Fujiya Y; Kuronuma K; Nakata H; Fukudo M; Takahashi S
J Infect Chemother; 2021 Jul; 27(7):1051-1057. PubMed ID: 33902990
[TBL] [Abstract][Full Text] [Related]
35. Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial.
Beigmohammadi MT; Bitarafan S; Hoseindokht A; Abdollahi A; Amoozadeh L; Mahmoodi Ali Abadi M; Foroumandi M
Trials; 2020 Jul; 21(1):614. PubMed ID: 32631405
[TBL] [Abstract][Full Text] [Related]
36. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment:
Yildiz Pekoz A; Akbal Dagistan O; Fael H; Culha M; Erturk A; Basarir NS; Sahin G; Serhatli M; Cakirca G; Tekin S; Sen LS; Sevim M; Mulazimoglu Durmusoglu L; Yegen BC
Drug Deliv; 2022 Dec; 29(1):2846-2854. PubMed ID: 36062490
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic.
de Hoog MLA; Sluiter-Post JGC; Westerhof I; Fourie E; Heuvelman VD; Boom TT; Euser SM; Badoux P; Reusken C; Bont LJ; Sanders EAM; Jaddoe VWV; Herpers BL; Eggink D; Wildenbeest JG; Duijts L; van Houten MA; Bruijning-Verhagen PCJL
JAMA Netw Open; 2022 Oct; 5(10):e2237522. PubMed ID: 36264578
[TBL] [Abstract][Full Text] [Related]
39. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
[TBL] [Abstract][Full Text] [Related]
40. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
